Brokerages expect that Prevail Therapeutics Inc. (NASDAQ:PRVL) will report ($0.50) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Prevail Therapeutics’ earnings. The business is scheduled to report its next earnings report on Wednesday, November 13th.
On average, analysts expect that Prevail Therapeutics will report full year earnings of ($2.51) per share for the current year, with EPS estimates ranging from ($3.33) to ($2.07). For the next fiscal year, analysts anticipate that the business will report earnings of ($2.11) per share, with EPS estimates ranging from ($2.48) to ($1.87). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Prevail Therapeutics.
Prevail Therapeutics (NASDAQ:PRVL) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.24) by $0.66.
Prevail Therapeutics stock traded up $0.02 during mid-day trading on Monday, hitting $10.92. 26,715 shares of the stock were exchanged, compared to its average volume of 144,156. Prevail Therapeutics has a 12 month low of $7.41 and a 12 month high of $16.90. The firm’s fifty day moving average price is $11.10.
In related news, Director Carl L. Gordon acquired 882,352 shares of the stock in a transaction dated Monday, June 24th. The stock was bought at an average price of $17.00 per share, for a total transaction of $14,999,984.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.
Large investors have recently added to or reduced their stakes in the company. Blackstone Group Inc bought a new stake in shares of Prevail Therapeutics in the 2nd quarter valued at $66,000. EcoR1 Capital LLC bought a new stake in Prevail Therapeutics during the 2nd quarter valued at $31,582,000. Marshall Wace North America L.P. bought a new stake in Prevail Therapeutics during the 2nd quarter valued at $520,000. Vanguard Group Inc. bought a new stake in Prevail Therapeutics during the 2nd quarter valued at $1,015,000. Finally, DRW Securities LLC bought a new stake in Prevail Therapeutics during the 2nd quarter valued at $652,000. Institutional investors own 8.19% of the company’s stock.
Prevail Therapeutics Company Profile
Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.